4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE 246.5 MG / 100 ML
LYSINE (L-LYSINE HYDROCHLORIDE) : 246.5 MG / 100 ML SODIUM CHLORIDE : 77 MG / 100 ML TRYPTOPHAN : 76.5 MG / 100 ML DEXTROSE : 10 G / 100 ML MAGNESIUM CHLORIDE : 51 MG / 100 ML L-TYROSINE : 17 MG / 100 ML SODIUM ACETATE : 297 MG / 100 ML SERINE : 212.5 MG / 100 ML L-ARGININE : 489 MG / 100 ML L-VALINE : 246.5 MG / 100 ML L-PROLINE : 289 MG / 100 ML HISTIDINE : 204 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 261 MG / 100 ML L-THREONINE : 178.5 MG / 100 ML L-LEUCINE : 310 MG / 100 ML L-ALANINE : 880 MG / 100 ML L-PHENYLALANINE : 238 MG / 100 ML L-ISOLEUCINE : 255 MG / 100 ML GLYCINE : 438 MG / 100 ML METHIONINE : 170 MG / 100 ML · DIN 02142414 · BAXTER CORPORATION CLINTEC NUTRITION DIVISION
Health Canada status: CANCELLED POST MARKET
What is 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE?
4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE 246.5 MG / 100 ML contains LYSINE (L-LYSINE HYDROCHLORIDE) : 246.5 MG / 100 ML SODIUM CHLORIDE : 77 MG / 100 ML TRYPTOPHAN : 76.5 MG / 100 ML DEXTROSE : 10 G / 100 ML MAGNESIUM CHLORIDE : 51 MG / 100 ML L-TYROSINE : 17 MG / 100 ML SODIUM ACETATE : 297 MG / 100 ML SERINE : 212.5 MG / 100 ML L-ARGININE : 489 MG / 100 ML L-VALINE : 246.5 MG / 100 ML L-PROLINE : 289 MG / 100 ML HISTIDINE : 204 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 261 MG / 100 ML L-THREONINE : 178.5 MG / 100 ML L-LEUCINE : 310 MG / 100 ML L-ALANINE : 880 MG / 100 ML L-PHENYLALANINE : 238 MG / 100 ML L-ISOLEUCINE : 255 MG / 100 ML GLYCINE : 438 MG / 100 ML METHIONINE : 170 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02142414, held by BAXTER CORPORATION CLINTEC NUTRITION DIVISION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 05-Aug-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE called?
The same molecule, COMBINATIONS, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ekyflogyl | Latin | Iceland |
| OTIPAX | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02142414 |
|---|---|
| Brand name | 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE |
| Generic / active ingredient | LYSINE (L-LYSINE HYDROCHLORIDE) : 246.5 MG / 100 ML SODIUM CHLORIDE : 77 MG / 100 ML TRYPTOPHAN : 76.5 MG / 100 ML DEXTROSE : 10 G / 100 ML MAGNESIUM CHLORIDE : 51 MG / 100 ML L-TYROSINE : 17 MG / 100 ML SODIUM ACETATE : 297 MG / 100 ML SERINE : 212.5 MG / 100 ML L-ARGININE : 489 MG / 100 ML L-VALINE : 246.5 MG / 100 ML L-PROLINE : 289 MG / 100 ML HISTIDINE : 204 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 261 MG / 100 ML L-THREONINE : 178.5 MG / 100 ML L-LEUCINE : 310 MG / 100 ML L-ALANINE : 880 MG / 100 ML L-PHENYLALANINE : 238 MG / 100 ML L-ISOLEUCINE : 255 MG / 100 ML GLYCINE : 438 MG / 100 ML METHIONINE : 170 MG / 100 ML |
| Manufacturer | BAXTER CORPORATION CLINTEC NUTRITION DIVISION |
| Strength | 246.5 MG / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA10 COMBINATIONS |
| AHFS class | 40:50.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 05-Aug-2015 |
| Original market date | 1994-12-15 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02142414 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2142414 |
| Brand name | 4.25% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE |
| Active ingredient / INN | LYSINE (L-LYSINE HYDROCHLORIDE) : 246.5 MG / 100 ML SODIUM CHLORIDE : 77 MG / 100 ML TRYPTOPHAN : 76.5 MG / 100 ML DEXTROSE : 10 G / 100 ML MAGNESIUM CHLORIDE : 51 MG / 100 ML L-TYROSINE : 17 MG / 100 ML SODIUM ACETATE : 297 MG / 100 ML SERINE : 212.5 MG / 100 ML L-ARGININE : 489 MG / 100 ML L-VALINE : 246.5 MG / 100 ML L-PROLINE : 289 MG / 100 ML HISTIDINE : 204 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 261 MG / 100 ML L-THREONINE : 178.5 MG / 100 ML L-LEUCINE : 310 MG / 100 ML L-ALANINE : 880 MG / 100 ML L-PHENYLALANINE : 238 MG / 100 ML L-ISOLEUCINE : 255 MG / 100 ML GLYCINE : 438 MG / 100 ML METHIONINE : 170 MG / 100 ML |
| ATC code | B05BA10 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05 |
| AHFS class | 40:50.00* ; See footnote |
| Health Canada schedule | Ethical |
| Biosimilar biologic | No |
| Market authorization holder | BAXTER CORPORATION CLINTEC NUTRITION DIVISION |
Which pack is which?
| Strength on the label | 246.5 MG / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
What can be used instead?
Other Canadian products sharing ATC code B05BA10 COMBINATIONS. 22 of 79 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLINIMIX | 10 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498456 |
| CLINIMIX | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013932 |
| CLINIMIX | 230 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013886 |
| CLINIMIX | 310 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02046709 |
| CLINIMIX | 464 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498464 |
| CLINIMIX | 520 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013940 |
| CLINIMIX | 690 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498448 |
| CLINIMIX E | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02013967 |
| CLINIMIX E | 261 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02498413 |
| CLINIMIX E | 290 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02014076 |
Who else supplies COMBINATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does COMBINATIONS cost around the world?
COMBINATIONS is listed on 4 national price registers Nexara tracks, across 8 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Hungary | producer price (ex-factory) | 5 | 5 | 03 Sep 2026 |
| Czechia | max producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
| Luxembourg | reimbursement | 1 | 1 | 05 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.